Silexion Therapeutics

Company Overview

Snapshot

Founded in November 2008 by Amotz Shemi, PhD, Silexion Therapeutics operates with 11–50 employees. The company has raised $27.65 million across six funding rounds, with Esperante Ventures as an investor. In August 2024, Silexion Therapeutics went public on NASDAQ following a SPAC event.

Business overview

Silexion Therapeutics is a developmental stage company focused on creating innovative treatments for pancreatic cancer. Leveraging RNA interference technology, the company develops RNA-based therapeutics designed to silence specific genes implicated in pancreatic cancer growth and metastasis. Its core product, LODER™, has shown positive efficacy results in Phase 2 clinical trials, and the company is enhancing this first-generation product to improve clinical efficacy against pancreatic cancer. Silexion Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market with its drug discovery and biological therapy solutions.

Strategic signal

In June 2026, Silexion Therapeutics received approval from Germany's BfArM to initiate a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer, following a similar approval from the Israeli Ministry of Health in March 2026. This dual regulatory clearance in key European and Middle Eastern markets signals significant progress in the clinical development of its next-generation RNA silencing therapy, indicating a strong forward trajectory for the company's therapeutic pipeline and potential market expansion.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Silexion Therapeutics?

In June 2026, Silexion Therapeutics received approval from Germany's BfArM to initiate a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer.

When did Silexion Therapeutics go public?

Silexion Therapeutics went public on NASDAQ in August 2024, following a SPAC event with Moringa Acquisition Corp.

What was the outcome of Silexion Therapeutics' preclinical studies for SIL204 in May 2025?

In May 2025, Silexion Therapeutics announced groundbreaking preclinical results for SIL204, demonstrating strong efficacy in pancreatic, colorectal, and lung cancers.

What was a key development regarding SIL204's manufacturing and clinical trials in May 2026?

In May 2026, Silexion Therapeutics announced the initiation of GMP clinical supply manufacturing of SIL204 with a leading global CDMO and received approval for a Phase 2/3 trial from Tel Aviv Sourasky Medical Center.

What was the outcome of Silexion Therapeutics' preclinical data for SIL204 in March 2025?

In March 2025, Silexion Therapeutics reported groundbreaking positive initial data from systemic administration of SIL204 in orthotopic pancreatic cancer models.